What’s new in the management of metastatic bone disease

Tsukamoto, Shinji; Errani, Costantino; Kido, Akira; Mavrogenis, Andreas F.

doi:10.1007/s00590-021-03136-4

Cited by 9 publications

(14 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8 In the present investigation, we were interested in assessing disparities in survival for patients with MBD, given that bone is one of the most common sites of metastatic disease 5,8,9 and also that metastatic disease is the most common malignant process affecting the skeletal system 4,10 Patients with MBD have advanced systemic disease and face unique treatment challenges. 6,11,12 MBD is associated with significant morbidity and functional compromise. Historically, patient with MBD at initial presentation had reduced life expectancy with treatment efforts primarily focused on pain control and palliation.…”

Section: Introductionmentioning

confidence: 99%

“…Fortunately, with recent advances in treatment, the life expectancy for patients with MBD has improved considerably. 11,12 Thus, while patients with MBD are now living longer, they face new challenges related to optimizing their quality of life. 6 Specifically, sarcopenia, cachexia, and pain associated with MBD have the potential to shift a patients primary concern from longevity to more nuanced anxieties pertaining to simple activities of daily living, 6,13,14 kinesiophobia, and low pain self-efficacy.…”

Section: Introductionmentioning

confidence: 99%

“…Patients with MBD have advanced systemic disease and face unique treatment challenges 6,11,12 . MBD is associated with significant morbidity and functional compromise.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Socioeconomic and insurance‐related disparities in disease‐specific survival among patients with metastatic bone disease

Jawad

Pollock

Zeitlinger

et al. 2022

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background: Approximately 5% of cancer patients in the United States presented with metastatic bone disease (MBD) at diagnosis. Current study explores the disparities in survival for patients with MBD. Methods: Patients with the diagnosis of MBD at presentation for the five most common primary anatomical sites were extracted from Surveillance, Epidemiology, and End Results Census tract-level dataset (2010-2016). Kaplan-Meier and Cox Proportional Hazard models were used to evaluate survival, and prognostic factors for each cohort. Prognostic significance of socioeconomic status (SES) and insurance status were ascertained.Results: The five most common anatomical-sites with MBD at presentation included "lung" (n = 59 739), "prostate" (n = 19 732), "breast" (n = 16 244), "renal and urothelium" (n = 7718) and "colon" (n= 3068). Lower SES was an independent risk factor for worse disease-specific survival (DSS) for patients with MBD originating from lung, prostate, breast and colon. Lack of insurance was an independent risk factor for worse DSS for MBD patients with primary tumors in lung and breast.Conclusions: MBD patients from the five most common primary sites demonstrated SES and insurance-related disparities in disease-specific survival. This is the first and largest study to explore SES and insurance-related disparities among patients specifically afflicted with MBD. Our findings highlight vulnerability of patients with MBD across multiple primary sites to financial toxicity.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Socioeconomic and insurance‐related disparities in disease‐specific survival among patients with metastatic bone disease

Jawad

Pollock

Zeitlinger

et al. 2022

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…Life expectancy has also increased thanks to targeted therapies or immunotherapies. As a result, metastatic bone cancers now have a better survival prognosis [ 3 , 4 , 5 , 6 ], and more patients might need surgeries for these metastatic conditions [ 7 , 8 ]. These complex surgical procedures are decided in multidisciplinary meetings when medical treatments and radiation therapy are no longer an option.…”

Section: Introductionmentioning

confidence: 99%

Functional and Survival Outcomes of Patients following the Harrington Procedure for Complex Acetabular Metastatic Lesions

et al. 2022

View full text Add to dashboard Cite

Background: The Harrington surgical technique makes it possible to manage complex, extensive bone lesions using pins and cement to consolidate bone for acetabular cup positioning. However, it may be associated with a high reoperation rate, and the functional results of this surgery are not precisely described in the literature. Methods: In a monocentric retrospective study including all patients operated on using the Harrington procedure associated with THA between 2005 and 2020, we aimed to assess preoperative and postoperative function, reoperation-free survival, and overall survival. Results: Functional improvement was significant for Parker scores (preoperative: 3.6 ± 2.0; 6-month follow-up: 6.6 ± 3.2; 12-month follow-up: 7.6 ± 2.1) and Musculoskeletal Tumor Society (MSTS) scores (preoperative: 31.1 ± 16.2%; 6-month follow-up: 67.7 ± 30.6%; 12-month follow-up: 82.4 ± 24.0%). Of the 21 patients included, the reoperation-free survival rate was 76.1% [CI 95%: 58.1–99.7] at six and twelve months, with the main complications being pin migration (50.0%) and infection (25%). The patient overall survival rate was 76.2% [95% CI: 59.9–96.7] at six months and 61.9% [95% CI: 59.9–96.7] at 12 months. Discussion: These results underlined significant functional improvements following a conventional Harrington procedure, with acceptable reoperation rates.

show abstract

“…Minimally invasive techniques seem to be effective for both pain relief and local tumor control, suggesting that their use may increase in the near future [ 18 , 20 , 24 ]. The goal of the management of patients with metastatic bone disease is pain relief and an improvement in the quality of remaining life [ 25 ]. This Special Issue on the “Treatment of Bone Metastasis” reviews recent findings on the prognosis and treatment of patients with metastatic bone disease in the hopes of stimulating the scientific community to continue research on novel, less invasive therapies.…”

mentioning

confidence: 99%